Clinical trial · Interventional
the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome
The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to affect more than 5% of the population and is associated with chronically elevated serum androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive disease during pregnancy,and preterm birth,which is partially related with the hyperandrogenic environment.Diane-35 has been proved to be the most effective anti-androgenic drug.At present, there is no direct evidence that Diane-35 has a positive effect on the clinical outcome of polycystic ovary syndrome patients undergoing In-vitro fertilization/Intracytoplasmic sperm injection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diane-35 pretreatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- diane-35
- description
- Diane-35 pretreatment from the third day of menstrual cycle
- interventionNames
- Drug: Diane-35 pretreatment
- type
- NO_INTERVENTION
- label
- blank control
Primary outcomes (1)
- measure
- fertilization rate
- timeFrame
- up to 2years
Secondary outcomes (1)
- measure
- implantation rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed polycystic ovary syndrome patients according to Rotterdam criteria * with hyperandrogenism and/or clinical hyperandrogenic manifestations * no other oral contraceptives treatment for at least 3 months before this experiment * no any other assisted reproductive therapy * accompanied with fallopian tube and/or male factors * normal hepato-/nephro- function Exclusion Criteria: * oral contraceptive pills contraindications, eg.Deep Venous Thrombosis * smoking, drunk * exclude other infertile factors, eg.endometriosis, abnormal thyroid function, etc.
References
Publications (0)
Data not yet available